Disease · MONDO_0021656

nongerminomatous germ cell tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nongerminomatous germ cell tumor. Diseases, record MONDO_0021656. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021656

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nongerminomatous germ cell tumor; Open Targets
Open Targets ID: MONDO_0021656; Open Targets
Other names: Nongerminomatous germ cell tumor Including central nervous system, Nongerminomatous germ cell tumour, Nongerminomatous germ cell tumour Including central nervous system, non-dysgerminomatous germ cell tumor, non-dysgerminomatous germ cell tumour, non-germinomatous germ cell tumor, non-germinomatous germ cell tumour, non-seminomatous germ cell tumor, non-seminomatous germ cell tumour; Open Targets
NCI Thesaurus: C121619; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 9 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BLEOMYCIN	CHEMBL6067492		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BLEOMYCIN SULFATE	CHEMBL6067493		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOPOSIDE PHOSPHATE	CHEMBL1200645	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
THIOTEPA	CHEMBL671	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00104676	Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors	Phase 3	263	2021-06-07	Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor	BLEOMYCIN, CISPLATIN, ETOPOSIDE, IFOSFAMIDE, OXALIPLATIN, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT01602666	Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors	Phase 2	262	2020-12-16	Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma	CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT02034110	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	Phase 2	206	2023-08-21	Cancer	DABRAFENIB, TRAMETINIB	Its record names the disease	ClinicalTrials.gov
NCT02689219	Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors	Phase 2	18	2019-11-26	Germ Cell Tumors, Testis Cancer, Testicular Cancer, Embryonal Carcinoma, Nonseminomatous Germ Cell Tumor	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT00912912	Sunitinib Malate in Refractory Germ Cell Tumors	Phase 2	5	2016-01-27	Genitourinary Disease	SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT03067181	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors	Phase 3	1,780		Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor	BLEOMYCIN SULFATE, CARBOPLATIN, CISPLATIN, ETOPOSIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00293358	Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain	Phase 3	500		Brain and Central Nervous System Tumors	CARBOPLATIN, CISPLATIN, ETOPOSIDE PHOSPHATE, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT04684368	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT	Phase 2	160		Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor	CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, THIOTEPA	Its record names the disease	ClinicalTrials.gov
NCT02115165	A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors	Phase 2	34		Non-seminomatous Germ-cell Tumors	CABAZITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02784054	Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor	Phase 2	25		Intracranial Non-germinomatous Germ Cell Tumor	BLEOMYCIN, CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, MELPHALAN, THIOTEPA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) vs Stratum 2 Localized Germinoma: deaths from any cause	13 of 107	2 of 137	244	NCT01602666	Trial comparisons
Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) vs Stratum 2 Localized Germinoma: serious adverse events	5 of 107	1 of 137	244	NCT01602666	Trial comparisons
Arm I vs Arm II: deaths from any cause	61 of 98	66 of 105	203	NCT00104676	Trial comparisons
Arm I vs Arm II: serious adverse events	37 of 98	58 of 105	203	NCT00104676	Trial comparisons
CD30 Negative/Unknown vs CD30 Positive: Number of Patients With Treatment Related Adverse Events Grade 3 or Above	0 of 11	2 of 7	18	NCT02689219	Trial comparisons
CD30 Negative/Unknown vs CD30 Positive: deaths from any cause	8 of 11	6 of 7	18	NCT02689219	Trial comparisons
CD30 Negative/Unknown vs CD30 Positive: serious adverse events	2 of 11	3 of 7	18	NCT02689219	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39167741	DERIVED	1	PubMed
37934000	DERIVED	1	PubMed
37783480	DERIVED	1	PubMed
37219859	DERIVED	1	PubMed
37059834	DERIVED	1	PubMed
36108341	DERIVED	1	PubMed
34838156	DERIVED	1	PubMed
33633029	DERIVED	1	PubMed
32818466	DERIVED	1	PubMed
31545689	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021656

GET https://conductscience.org/api/diseases/v1/MONDO_0021656/targets?page=2

API reference For AI assistants